-
July 26, 2022|GEN
This is Epic: Epigenomic CRISPR Startup Goes Big by Thinking Small
Epic Bio, founded by Stanford bioengineer Stanley Qi, builds pipeline with tiniest Cas protein, epigenetic modulators, a platform that combines them, and proceeds from $55M Series A.
-
July 26, 2022|BioPharma Dive
Epigenetic editing: a tunable CRISPR alternative
The startup is funded by Horizons Ventures and led by Amber Salzman, who has headed multiple genetic medicine companies, most recently Adverum Biotechnologies.
-
July 15, 2022|BioWorld
CRISPR co-inventor’s Epic Bio launches with $55M series A
Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of Epic Bio, a new company founded by Stanley Qi.
-
July 13, 2022|BioCentury
Epic Bio: Epigenome editing via compact components
Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
-
July 12, 2022|San Francisco Business Times
Why Hong Kong's richest person is betting on a Peninsula biotech startup
By not cutting out the bad part of a gene before replacing it with a correct DNA sequence — the essence of the CRISPR editing technology — the South San Francisco company believes its platform can reduce potential errors and side effects to fix a range of genetic diseases.
-
July 12, 2022|Endpoints News
Big Pharma vet teams with former Doudna pupil to launch new epigenome startup
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
-
July 12, 2022|FierceBiotech
An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering
CRISPR co-inventor Stanley Qi, Ph.D., is out with a new biotech that wants to make a big splash by going small.
